See All Slides -

Slides

Presentation TCT 2015

Making the Case for: IVUS in Left Main Disease

Presenter: David E. Kandzari, Francesco Liistro

October 15, 2015

Presentation TCT 2015

How Can Adoption of Radial Approach Be Accelerated?

Presenter: Olivier F. Bertrand, Ian C. Gilchrist

October 15, 2015

Presentation TCT 2015

The Lifetech Iron-Based BRS: Differentiating Features and Challenges

Presenter: Alexandre Abizaid, Pieter C. Smits, Deyuan Zhang

October 15, 2015

Presentation TCT 2015

RESPECT: A Prospective Randomized Trial of PFO Closure in Patients With Cryptogenic Stroke Long-term Results

Presenter: John D. Carroll, Ioanna Kosmidou

October 15, 2015

Presentation TCT 2015

HCM Ablation Step-by-Step Approach, Complications, and Long-term Outcomes

Presenter: John S. Douglas Jr, Sherif F. Nagueh, Valerian Fernandes

October 15, 2015

Presentation TCT 2015

Making the Case for: FFR in Left Main Disease

Presenter: David E. Kandzari, Michalis Hamilos

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Presenter: Isaac George, Augusto D. Pichard, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

Current and Future Strategies for EVAR Follow-up and Endoleak Surveillance

Presenter: Clifford J. Buckley, Zvonimir Krajcer, Robert A. Lookstein

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Advertisement

Slides

Making the Case for: IVUS in Left Main Disease

How Can Adoption of Radial Approach Be Accelerated?

The Lifetech Iron-Based BRS: Differentiating Features and Challenges

RESPECT: A Prospective Randomized Trial of PFO Closure in Patients With Cryptogenic Stroke Long-term Results

HCM Ablation Step-by-Step Approach, Complications, and Long-term Outcomes

Making the Case for: FFR in Left Main Disease

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Current and Future Strategies for EVAR Follow-up and Endoleak Surveillance

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content